These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20685314)

  • 1. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
    Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
    Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
    Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
    Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
    J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
    Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
    Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.
    Haid S; Windisch MP; Bartenschlager R; Pietschmann T
    J Virol; 2010 Jan; 84(2):964-75. PubMed ID: 19889758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
    Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
    Krieger SE; Zeisel MB; Davis C; Thumann C; Harris HJ; Schnober EK; Mee C; Soulier E; Royer C; Lambotin M; Grunert F; Dao Thi VL; Dreux M; Cosset FL; McKeating JA; Schuster C; Baumert TF
    Hepatology; 2010 Apr; 51(4):1144-57. PubMed ID: 20069648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human claudin-1-derived peptide inhibits hepatitis C virus entry.
    Si Y; Liu S; Liu X; Jacobs JL; Cheng M; Niu Y; Jin Q; Wang T; Yang W
    Hepatology; 2012 Aug; 56(2):507-15. PubMed ID: 22378192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
    Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
    PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
    Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
    J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
    Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
    J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
    Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
    J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.
    Sekhar V; Pollicino T; Diaz G; Engle RE; Alayli F; Melis M; Kabat J; Tice A; Pomerenke A; Altan-Bonnet N; Zamboni F; Lusso P; Emerson SU; Farci P
    PLoS Pathog; 2018 Mar; 14(3):e1006916. PubMed ID: 29538454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
    Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
    J Virol; 2018 May; 92(10):. PubMed ID: 29491159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.
    Anggakusuma ; Colpitts CC; Schang LM; Rachmawati H; Frentzen A; Pfaender S; Behrendt P; Brown RJ; Bankwitz D; Steinmann J; Ott M; Meuleman P; Rice CM; Ploss A; Pietschmann T; Steinmann E
    Gut; 2014 Jul; 63(7):1137-49. PubMed ID: 23903236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.
    Tawar RG; Colpitts CC; Timm J; Fehm T; Roggendorf M; Meisel H; Meyer N; Habersetzer F; Cosset FL; Berg T; Zeisel MB; Baumert TF
    Hepatology; 2015 Sep; 62(3):726-36. PubMed ID: 26010076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection.
    Liu S; Yang W; Shen L; Turner JR; Coyne CB; Wang T
    J Virol; 2009 Feb; 83(4):2011-4. PubMed ID: 19052094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.
    Evans MJ; von Hahn T; Tscherne DM; Syder AJ; Panis M; Wölk B; Hatziioannou T; McKeating JA; Bieniasz PD; Rice CM
    Nature; 2007 Apr; 446(7137):801-5. PubMed ID: 17325668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
    Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
    Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.